Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2026 (FY2025)

from the beginning

Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2026 (FY2025)

• Forward-Looking Statements and Use of Document

• Highlights: Strong Earnings Results Exceeding Guidance

• P&L, FCF

• OP Variance Analysis (Q3): Growth due to strong sales

• OP Variance Analysis (Q3 YTD): Contribution from pricing measures and strong sales

• C&V: TIS led the way, continued expansion mainly in North America

• TMCS: Increased sales in PS contributed to revenue and profit growth

• TBCT: Plasma innovation drove revenue growth, supported improved profitability

• OrganOx: Rapid revenue growth by increasing liver transplants and market share

• Revenue by Region: Americas strongly drove overall growth

• Toward Achieving FY25/GS26 and Beyond

References

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustments

• Adjusted Operating Profit: Quarterly Trend

• CAPEX, Depreciation and Amortization, R&D Expenses

• Free Cash Flow

• Cash Flow (Q3)

• Cash Flow (Q3 YTD)

• Foreign Exchange Sensitivity

@